Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia
| Autor: | Elias Jabbour, Hagop M. Kantarjian, Nicholas J. Short, Farhad Ravandi |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Health Services for the Aged medicine.medical_treatment Lymphoblastic Leukemia Philadelphia chromosome Antibodies Monoclonal Humanized 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Older patients Internal medicine Antibodies Bispecific medicine Humans Inotuzumab Ozogamicin Protein Kinase Inhibitors Aged Inotuzumab ozogamicin Aged 80 and over Chemotherapy Hematology business.industry Ponatinib Imidazoles Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Pyridazines chemistry 030220 oncology & carcinogenesis Blinatumomab Female business 030215 immunology medicine.drug |
| Zdroj: | Current hematologic malignancy reports. 13(2) |
| ISSN: | 1558-822X |
| Popis: | Older adults with acute lymphoblastic leukemia (ALL) have worse survival compared to their younger counterparts. Here, we review the reasons for the poorer outcomes of older patients with ALL and also summarize the current and future therapeutic approaches to ALL in the elderly population. The poor outcomes of older adults with ALL are driven largely by lack of tolerance to standard-dose chemotherapy, which leads to unacceptably high rates of myelosuppression-related deaths. Recent studies have shown promising results with the use of low-intensity or chemotherapy-free regimens in older patients with ALL, which are able to retain efficacy without excess toxicity. Novel antibody constructs such as inotuzumab ozogamicin and blinatumomab as well as potent later-generation tyrosine kinase inhibitors such as ponatinib hold significant promise in the management of ALL in the older adult. Innovative combination strategies may further improve the outcomes of these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink